Deegtal

Deegtal operates at the intersection of medical devices, artificial intelligence, and neurotechnology, with a narrow focus on accelerating epilepsy diagnosis from EEG data. Its differentiation is specialization: rather than presenting as a broad clinical analytics provider, the company targets a defined neurological workflow through dEEGtal Insight and automated EEG pattern recognition. Deegtal’s strongest documented positioning signals are its connection to Geneva University Hospitals, its October 2024 Innovation Prize, selection as the 2025 DayOne audience-award winner, and CHF 640,000 of Innosuisse support announced on Sep 23, 2025. These signals suggest institutional and ecosystem validation, but they do not establish broad commercial adoption. With an employee range of one to ten and approximately $1.94 million in disclosed funding, Deegtal remains an early-stage specialist rather than a scaled medical-AI platform.

Deegtal’s trajectory shows a progression from early accelerator and grant support toward a larger seed-backed and institutionally supported development program. Initial disclosed support included a $3,538 DayOne accelerator grant on Aug 23, 2024 and an $11,805 Venture Kick grant on Aug 26, 2024. The company then recorded a $1.12 million seed round led by the Wyss Center on Dec 13, 2024, followed by an $808,666 Innosuisse grant announced on Sep 23, 2025. Together, these four structured rounds total approximately $1.94 million, with grants representing a substantial share of disclosed financing. Recognition at the Geneva University Hospitals Innovation Prize in October 2024 and the DayOne Innovation Showcase audience award on Dec 16, 2025 provided additional validation. In 2026, appointing Ann Bunnenberg to the board marked an organizational inflection point toward stronger medtech governance and strategic leadership.